Why is Monopar Therapeutics stock down 7.6% today?

Traders Union
All News
Financial News
Monopar slides 7.68% today to $103.84

Highlights

Monopar Therapeutics maintains firm bullish momentum, trading above key moving averages across all major timeframes.
Despite dominant buying pressure, multiple signals—including RSI and CCI—indicate the stock is currently in overbought territory.
Expected five-day price range is $94.57 to $110.15, with 77% probability of an upside move if resistance at $104.01 breaks.

Anton Kharitonov, expert at Traders Union, identifies a sharp daily decline of 7.68% as a crucial warning sign despite mostly bullish technicals. He notes that price is at the day’s lows and intraday volatility is high, exposing Monopar Therapeutics to abrupt sentiment shifts. Kharitonov points out the overbought readings on the RSI and CCI, and finds the Stochastic RSI’s sell signal concerning for short-term traders. The lack of supporting news on the selloff increases uncertainty and risk for new entries. He concludes, "I remain cautious here, as technical overextension and heavy selling pressure raise the risk of a deeper correction."

Viktoras Karapetjanc, expert at Traders Union, sees opportunity for further gains in Monopar Therapeutics. He highlights the strong bullish structure, noting price holds above all major moving averages. Despite the absence of supportive news, he believes technical buy signals and market momentum are likely to prevail. Karapetjanc emphasizes, "With buyers firmly in control and momentum indicators flashing green, I see the bullish structure as intact and expect further growth toward $110.1525."

Sholanke Dele, market strategist, is skeptical about the stock’s near-term outlook given today’s heavy downside. He points out that the absence of fresh news despite the sharp drop raises concerns about underlying demand. Dele adds that overbought technical readings could quickly reverse sentiment if selling resumes. He warns, "Unless new catalysts surface, I expect more volatility and see downside risk toward $94.57."

Bullish momentum prevails as technicals flag overbought, mixed signals

Monopar Therapeutics is trading above its 20-day, 50-day, and 200-day moving averages ($100.453, $77.7399, and $70.656 respectively), indicating strong bullish momentum across all timeframes. The moving average alignment confirms a firm bullish structure, with immediate levels to watch at the near-term ceiling of $104.01 and the near-term floor at $102.3. Momentum remains robust as the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both suggest strong buy conditions. The Relative Strength Index (RSI) is elevated at 72.2293, flashing a buy signal and hinting at overbought conditions alongside the Commodity Channel Index (CCI) and Bull/Bear Power (BBP). Buyers are dominating intraday momentum, but both CCI and BBP forecasts indicate an overbought environment. The Stochastic RSI signals caution with a sell reading, creating a divergence in oscillator signals. Price action is near the day’s lows with intraday volatility at 7.19%. The tone remains heavy with continued pressure after the open, in contrast to prevailing bullish momentum signals.

Earlier, analysts noted that Monopar Therapeutics exhibited strong bullish momentum supported by operational developments and technical structure. With today's sharp pullback despite a continued bullish setup, traders should be alert for a potential shift in sentiment if the stock fails to reclaim the near-term ceiling in the coming sessions.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.